Literature DB >> 27417848

Reducing the risk of failure: biomarker-guided trial design.

Michael J Townsend1, Joseph R Arron2.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27417848     DOI： 10.1038/nrd.2016.124

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  5 in total

Review 1.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Authors:  Steven M Paul; Daniel S Mytelka; Christopher T Dunwiddie; Charles C Persinger; Bernard H Munos; Stacy R Lindborg; Aaron L Schacht
Journal:  Nat Rev Drug Discov       Date:  2010-02-19       Impact factor: 84.694

Review 2.  Stratified medicine in inflammatory disorders: From theory to practice.

Authors:  Joseph R Arron; Michael J Townsend; Mary E Keir; Brian L Yaspan; Andrew C Chan
Journal:  Clin Immunol       Date:  2015-04-28       Impact factor: 3.969

Review 3.  Biomarkers in the Evaluation and Management of Idiopathic Pulmonary Fibrosis.

Authors:  Argyris Tzouvelekis; Jose Herazo-Maya; Koji Sakamoto; Demosthenes Bouros
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

Review 4.  FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications.

Authors:  Kenneth G C Smith; Menna R Clatworthy
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

5.  Personalizing medicine for autoimmune and inflammatory diseases.

Authors:  Andrew C Chan; Timothy W Behrens
Journal:  Nat Immunol       Date:  2013-02       Impact factor: 25.606
  5 in total
  5 in total

1.  Impact of a five-dimensional framework on R&D productivity at AstraZeneca.

Authors:  Paul Morgan; Dean G Brown; Simon Lennard; Mark J Anderton; J Carl Barrett; Ulf Eriksson; Mark Fidock; Bengt Hamrén; Anthony Johnson; Ruth E March; James Matcham; Jerome Mettetal; David J Nicholls; Stefan Platz; Steve Rees; Michael A Snowden; Menelas N Pangalos
Journal:  Nat Rev Drug Discov       Date:  2018-01-19       Impact factor: 84.694

Review 2.  The "rights" of precision drug development for Alzheimer's disease.

Authors:  Jeffrey Cummings; Howard H Feldman; Philip Scheltens
Journal:  Alzheimers Res Ther       Date:  2019-08-31       Impact factor: 6.982

3.  A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 - Model Framework.

Authors:  Katharine V Rogers; Steven W Martin; Indranil Bhattacharya; Ravi Shankar Prasad Singh; Satyaprakash Nayak
Journal:  Clin Transl Sci       Date:  2020-08-21       Impact factor: 4.689

4.  Drug repurposing: a systematic review on root causes, barriers and facilitators.

Authors:  Nithya Krishnamurthy; Alyssa A Grimshaw; Sydney A Axson; Sung Hee Choe; Jennifer E Miller
Journal:  BMC Health Serv Res       Date:  2022-07-29       Impact factor: 2.908

5.  Potential biomarkers to follow the progression and treatment response of Huntington's disease.

Authors:  Marie-Hélène Disatnik; Amit U Joshi; Nay L Saw; Mehrdad Shamloo; Blair R Leavitt; Xin Qi; Daria Mochly-Rosen
Journal:  J Exp Med       Date:  2016-11-07       Impact factor: 14.307
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.